IL153513A - Pharmaceutical composition comprising a combination of a sulfonylurea antidiabetic agent and fbpase inhibitor and use thereof in the manufacture of medicaments for the treatment of diabetes - Google Patents

Pharmaceutical composition comprising a combination of a sulfonylurea antidiabetic agent and fbpase inhibitor and use thereof in the manufacture of medicaments for the treatment of diabetes

Info

Publication number
IL153513A
IL153513A IL153513A IL15351302A IL153513A IL 153513 A IL153513 A IL 153513A IL 153513 A IL153513 A IL 153513A IL 15351302 A IL15351302 A IL 15351302A IL 153513 A IL153513 A IL 153513A
Authority
IL
Israel
Prior art keywords
medicaments
diabetes
manufacture
treatment
combination
Prior art date
Application number
IL153513A
Other languages
Hebrew (he)
Original Assignee
Metabasis Therapeutics Inc
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabasis Therapeutics Inc, Daiichi Sankyo Co Ltd filed Critical Metabasis Therapeutics Inc
Publication of IL153513A publication Critical patent/IL153513A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL153513A 2000-07-06 2002-12-18 Pharmaceutical composition comprising a combination of a sulfonylurea antidiabetic agent and fbpase inhibitor and use thereof in the manufacture of medicaments for the treatment of diabetes IL153513A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21653100P 2000-07-06 2000-07-06
PCT/US2001/021557 WO2002003978A2 (en) 2000-07-06 2001-07-05 A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES

Publications (1)

Publication Number Publication Date
IL153513A true IL153513A (en) 2014-07-31

Family

ID=22807416

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15351301A IL153513A0 (en) 2000-07-06 2001-07-05 A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES
IL153513A IL153513A (en) 2000-07-06 2002-12-18 Pharmaceutical composition comprising a combination of a sulfonylurea antidiabetic agent and fbpase inhibitor and use thereof in the manufacture of medicaments for the treatment of diabetes

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL15351301A IL153513A0 (en) 2000-07-06 2001-07-05 A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES

Country Status (18)

Country Link
EP (1) EP1372660A2 (en)
JP (1) JP2004508297A (en)
KR (1) KR100854851B1 (en)
CN (2) CN100396283C (en)
AU (2) AU7327101A (en)
BR (1) BR0112212A (en)
CA (1) CA2412142A1 (en)
CZ (1) CZ20035A3 (en)
HU (1) HUP0301830A3 (en)
IL (2) IL153513A0 (en)
MX (1) MXPA02012713A (en)
NO (1) NO20030034L (en)
NZ (1) NZ523227A (en)
PL (1) PL365779A1 (en)
RU (1) RU2328308C2 (en)
SK (1) SK62003A3 (en)
WO (1) WO2002003978A2 (en)
ZA (1) ZA200300044B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6452098A (en) 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
EP1112275B9 (en) 1998-09-09 2004-03-10 Metabasis Therapeutics, Inc. Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase
CZ20023018A3 (en) 2000-03-08 2003-01-15 Metabasis Therapeutics, Inc. Novel fructose-1,6-bisphosphatase inhibitors containing aryl group
EP2050460A1 (en) 2001-09-24 2009-04-22 Imperial Innovations Limited PYY and agonists thereof for modification of feeding behaviour
JP4733922B2 (en) 2002-01-10 2011-07-27 インペリアル・イノベ−ションズ・リミテッド Correction of eating behavior
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
CA2551611C (en) 2003-12-26 2013-06-25 Kyowa Hakko Kogyo Co., Ltd. Thiazole derivatives for treating or preventing parkinson's disease
JP2008510018A (en) * 2004-08-18 2008-04-03 メタバシス・セラピューティクス・インコーポレイテッド Novel thiazole inhibitor of fructose-1,6-bisphosphatase
CN101119748A (en) * 2004-12-13 2008-02-06 第一三共株式会社 Pharmaceutical composition for treatment of diabetes
TW200738245A (en) * 2005-08-22 2007-10-16 Sankyo Co Pharmaceutical composition containing FBPase inhibitor
WO2007129522A1 (en) * 2006-04-10 2007-11-15 Daiichi Sankyo Company, Limited Preparation produced by dry process
EP2394647A1 (en) 2006-11-02 2011-12-14 Aestus Therapeutics, Inc. Methods of treating neuropathic pain by modulation of glycogenolysis or glycolysis pathways
TWI428346B (en) 2006-12-13 2014-03-01 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
CN103665043B (en) 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 A kind of tenofovir prodrug and its application in medicine
UY35065A (en) * 2012-10-08 2014-05-30 Lg Life Sciences Ltd COMBINED DRUG THAT INCLUDES GEMIGLIPTINE AND METFORMIN AND METHOD FOR PREPARATION
CN104788350A (en) * 2014-01-22 2015-07-22 天津大学 Method for acquiring medicinally-advantageous crystal form of tolbutamide through rapid cooling and crystallization
CN106831437B (en) * 2016-02-03 2019-06-21 华中师范大学 Ester type compound and its preparation method and application containing nitroethenyl group
CN114907285B (en) * 2021-02-10 2023-09-22 华中师范大学 Acylated saccharin compound, preparation method and application thereof, and hypoglycemic drug

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL93164A0 (en) * 1989-01-24 1990-11-05 Gensia Pharma Purine nucleosides and their medical use
WO1998039342A1 (en) * 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
AU6452098A (en) * 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
JP2001515482A (en) * 1997-03-07 2001-09-18 メタバシス・セラピューティクス・インコーポレイテッド Novel benzimidazole inhibitors of fructose-1,6-bisphosphatase
AU3087099A (en) * 1998-03-16 1999-10-11 Ontogen Corporation Piperazines as inhibitors of fructose-1,6-bisphosphatase (FBPase)
EP1112275B9 (en) * 1998-09-09 2004-03-10 Metabasis Therapeutics, Inc. Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase
PT1143955E (en) * 1998-12-24 2005-11-30 Metabasis Therapeutics Inc COMBINATION OF FBPASE INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES
ES2436610T3 (en) * 2000-01-21 2014-01-03 Novartis Ag Combinations containing dipeptidylpeptidase-IV inhibitors and antidiabetic agents
GB0015627D0 (en) * 2000-06-26 2000-08-16 Rademacher Group Limited Phosphoglycan messengers and their medical uses

Also Published As

Publication number Publication date
WO2002003978A2 (en) 2002-01-17
CA2412142A1 (en) 2002-01-17
JP2004508297A (en) 2004-03-18
ZA200300044B (en) 2004-05-06
KR100854851B1 (en) 2008-08-27
CN1599612A (en) 2005-03-23
CZ20035A3 (en) 2003-05-14
NZ523227A (en) 2005-04-29
MXPA02012713A (en) 2004-09-10
NO20030034D0 (en) 2003-01-03
RU2328308C2 (en) 2008-07-10
WO2002003978A3 (en) 2003-10-16
SK62003A3 (en) 2003-09-11
AU2001273271B2 (en) 2006-01-05
NO20030034L (en) 2003-03-05
AU7327101A (en) 2002-01-21
PL365779A1 (en) 2005-01-10
BR0112212A (en) 2003-12-30
HUP0301830A2 (en) 2003-11-28
IL153513A0 (en) 2003-07-06
KR20030031952A (en) 2003-04-23
EP1372660A2 (en) 2004-01-02
HUP0301830A3 (en) 2007-10-29
CN101301294A (en) 2008-11-12
CN100396283C (en) 2008-06-25

Similar Documents

Publication Publication Date Title
IL153513A (en) Pharmaceutical composition comprising a combination of a sulfonylurea antidiabetic agent and fbpase inhibitor and use thereof in the manufacture of medicaments for the treatment of diabetes
HUP0300642A3 (en) Pharmaceutical composition comprising a combination of metformin and another antidiabetic agent
HUP0301194A3 (en) Pharmaceutical compositions containing combinations of depeptidyl peptidase iv inhibitors and other antidiabetic agents and their use for the treatment of diabete mellitus
HUP0301452A3 (en) Pharmaceutical composition containing photochemotherapeutic agent and mucoadhesive agent and its use
IL148168A0 (en) Pharmaceutical composition of nateglinide and another antidiabetic agent
IL163278A (en) Formulations comprising glp-1 molecules and use thereof in the preparation of medicaments
IL220888A0 (en) 3,10 and 12 a substituted tetracyline compounds, pharmaceutical compositions comprising them and their use in the manufacture of medicaments
EP1600168A3 (en) A pyrrolidineacetamide derivative alone or in combination for treatment of CNS disorder
HK1078851A1 (en) 2-Indolinone-monoethanesulphonate and the use thereof in preparing a pharmaceutical composition
HUS1400025I1 (en) Phenethanolamine derivatives and pharmaceutical composition containing them
IL213597A0 (en) Compounds, pharmaceutical compositions comprising them and their use in the manufacture of medicaments
HUP0302550A3 (en) Glucopyranosyloxypyrazole derivatives and use thereof in medicines and pharmaceutical compositions containing them
IL203923A (en) Benzamide compounds, pharmaceutical compositions comprising them, use thereof in the preparation of medicaments and as medicaments and processes for the preparation of such compounds
HUP0104579A3 (en) Glp-1 analogues, pharmaceutical compositions comprising thereof and their use
HK1069974A1 (en) Pharmaceutical compositions comprising metformine and glibenclamide for the treatment of type-II diabetes mellitus
HUP0400037A2 (en) A pde 4 inhibitor and an anti-cholinergic agent in combination for treating obstructive airways diseases and pharmaceutical composition containing it
IL149139A0 (en) Pharmaceutical compositions containing metformin and glyburide
IL150383A0 (en) Glyburide and pharmaceutical compositions containing the same
IL156577A0 (en) Selective cathepsin s inhibitors and pharmaceutical compositions containing the same
HUP0402318A3 (en) Pharmaceutical composition comprising cyclosporin and use thereof
IL167406A (en) Lipophilic diesters of chelating agent and uses thereof for the preparation of medicaments for the inhibition of protease activity
IL155853A0 (en) Substituted cyclohexane derivatives and the use thereof in medicaments for treating cardiovascular diseases
HUP0402061A3 (en) Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, cox-2 inhibitor and a taxol
IL162101A (en) Crystalline form of a ribofuranosyluronamide derivative, pharmaceutical compositions comprising it, processes for its preparation and use thereof in the preparation of medicaments
IL160886A0 (en) Nicotine containing pharmaceutical formulations and use thereof

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees